BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114

Benzinga · 10/17 13:58
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $128 to $114.